Shares in U.K. biotech Synairgen were pummeled today as partner AstraZeneca revealed it was stopping development of its inhaled interferon beta therapy AZD9412.

Back in 2014, Roche spent $725 million upfront on California’s Seragon, but three years down the line, it has now canned work on its leading drug, ARN-810.

The Spanish government has ratcheted up the pressure on the European Council to make a quick decision on the new home of the region’s drug regulator.

The U.K.'s main pharma R&D lobby group has hit the national front pages today over threats the industry could start to leave the country.

Infectious disease specialist Arsanis has raised a solid chunk of cash as it picks up the Gates Foundation and Alphabet's GV as backers.

The Medicines Company and RNA biotech partner Alnylam have set out a new, large late-stage test for their next-gen anticholesterol candidate inclisiran, which…

AstraZeneca has taken another step toward the completion of its new headquarters and R&D hub in Cambridge, U.K.

Amgen has firmed up its lead in the race to bring the first CGRP inhibitor to market for migraine after presenting positive results from its two phase 3 trials.

Otsuka Pharmaceutical has expanded its anemia pact with Akebia Therapeutics.

Biotech